Animal Model Market

Global Animal Model Market Size (2023 to 2028)

The global animal model market is estimated to be valued at USD 2.68 billion by 2028 from USD 2 billion in 2023, growing at a CAGR of 6.12% from 2023 to 2028.

Impact of COVID-19 on the animal model market:

On January 30, 2020, the outbreak of COVID-19 was declared by the World Health Organisation as a public health emergency of international significance. Because of the peculiar characteristics of the COVID-19 pandemic, experts anticipate that it would have a considerable impact on the market for animal models as these are used in the investigation and development of antiviral drugs and vaccines. Animal models are being used by an increasing number of researchers to improve their understanding of the pathophysiology of SARS-CoV-2 infection and the immunological responses of hosts, as well as to accelerate the development of vaccines and medications for the prevention and treatment of COVID-19. However, as new strains of SARS-CoV-2 and other diseases emerge, along with new drug molecules being developed, the demand for research that utilizes animal models may increase even further in the future. As scientists strive to develop effective therapies and prophylactic immunizations for COVID-19, they are conducting an increasing number of research on COVID-19 in animals.

In addition, it was believed that K18-hACE transgenic mice were a fair model of COVID-19. In recent years, there has been a major increase in the need for a considerable number of animal models all over the world. This is because researchers are rushing to verify the safety and effectiveness of novel compounds before putting them through human trials. During the COVID-19 public health emergency, the Food and Drug Administration (FDA) implemented several different initiatives to ensure that high-quality treatments were readily available to mount an effective response. As a direct consequence of this, the utilization of this SARS-CoV-2 animal model at research facilities has seen a significant rise in recent years.

The need for increased funding for research and development (R&D) projects focusing on enhanced genetically modified models has been stressed by several government agencies and private industry entities. These enormous endeavors were undertaken to assist with the crucial need for speedy evaluation of prospective drugs and clinical trials of immunization leading to a positive impact on the animal model market.

MARKET DRIVERS:

The increasing need for animal models to be utilized in manufacturing and quality assurance is the primary factor driving the global animal model market growth. For instance, the use of CRISPR/Cas9-based genome editing is rapidly becoming a strong tool for treating human genetic illnesses including cardiovascular disease, neuro-disorders, and cancer. This has led to an increase in the need for animal genetic models for the research and treatment of these ailments. The growth of the CRISPR/Cas-9 market is being driven by the proliferation of this technology. Growing investment in research using animals has the potential to fuel the growth rate of the animal model market in the years to come.

Growing investments in the R&D of animal models are further contributing to the market growth. Over the past few years, the U.S. has significantly increased its investments in research and development for animal models. The growing investments in these research methodologies are also contributed to by the increasing assistance that government organizations and biopharmaceutical companies throughout the world are providing for research programs involving humanized and knockout animal models. This network has put attention on mouse genetics for disease modeling by increasing the integration of mouse genetics, cell and tissue systems, and deep phenotyping with human or clinical genomes and pathology. This is anticipated to improve both diagnosis and therapy.

MARKET RESTRAINTS:

The existence of regulations that mandate the humane treatment of animals is one of the major factors hampering market growth. In recent years, there has been a rise in the prevalence of the utilization of 3D-printed mouse models as an alternative to the employment of traditional mouse models. The price of these is far fairer when compared to that of humanized mouse models. Because of this achievement, the industry of mouse models now has access to new opportunities for 3D printing. The fact that osteogenesis was reproducible and reliable in this study is encouraging news for the development of new research and the improvement of clinical outcomes for patients. It provides the door for the rapid and inexpensive manufacturing of components that are suited to a particular imaging study, animal species, animal weight, or even a single animal that is not often utilized in preclinical research.

REPORT COVERAGE:

This research report on the global animal model market has been segmented and sub-segmented based on the animal type, application, end-user, and region.

Animal Model Market - By Animal Type:

• Mice
• Birds
• Fish
• Cattles

Based on animal type, the mice segment is predicted to account for the largest share of the global market during the forecast period. Mice has the physiological similarities they have with humans and their close phylogenetic relationship to us, as well as the relative simplicity with which they can be maintained and bred in a laboratory setting.

Animal Model Market - By Application:

• Research and Development
• Production and Quality Control
• Academics
• Others

Based on application, the R&D segment is anticipated to play the leading role in the global animal model market during the forecast period owing to the growing incidence of infectious diseases.

Animal Model Market - By End-User:

• Research Institutes
• Pharmaceutical Companies
• CRO (Contract Research Organizations)
• Educational Institutes

Based on end-user, the pharmaceutical segment is expected to hold the major share of the global market during the forecast period. The pharmaceutical industry has been undertaking an increasing number of preclinical research for the development of novel medications to respond to the vast unmet requirements of patients located all over the world.

Animal Model Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Rest of the World

North America currently accounts for the major share of the global market and is anticipated to hold the domination in the worldwide market during the forecast period. The growing number of investments in animal model research and a shift in the approach taken by the regulatory bodies in charge of the matter contribute to the growth of the North American market. The increasing focus on drug discovery and rising demand for personalized medicine further fuel the growth of the North American market. The growing biomedical research in the U.S. and preclinical operations carried out by local clinical research organizations (CROs) and pharmaceutical enterprises favor the North American market growth. Because of the frequency of issues that are related to the use of certain drugs, the U.S. is witnessing a boom in the design and distribution of personalized medical devices. The efforts that have been made by the government of the United States to enhance the use of personalized medicine in the U.S. have contributed to the growing significance of research that is based on animal models.

KEY MARKET PLAYERS:

Horizon Discovery Group plc, Trans Genic Inc, The Jackson Laboratory, Genoway SA, Transposagen Biopharmaceuticals, Inc., Crown Bioscience, Inc., Envigo CRS SA, Eurofins Scientific SE, Charles River Laboratories International, Inc and Taconic Biosciences, Inc. are some of the major players in the global animal model market.

RECENT MARKET DEVELOPMENTS:

• In September of 2022, a revised framework was presented for the strategic relationship between Sigma-Aldrich Co. LL and genOway in the CRISPR/Cas9 area.
• In September 2022, according to new preclinical data that was made available by Enlivex Therapeutics Ltd, the combination of Allocetra with the chemotherapeutic medication Cisplatin resulted in a considerable improvement in the survival rate of a mouse model for mesothelioma.
• In January 2022, Orient BioResource Centre, Inc., a preclinical contract research organization (CRO) and animal model supplier was purchased by Inotiv from Orient Bio, Inc.